Xbrane appoints three seasoned board members with vast experience within Life Science’s and Pharmaceuticals
Stockholm, Sweden – 2015-06-26 – Xbrane, a commercial phase Biopharmaceutical Company specialized in High Demand Complex Generics, announce the appointment of three new board members, Maris Hartmanis Ph.D., Karin Wingstrand M.Sc. and Peter Edman Ph.D. In addition, the Board of Directors consists of chairman Saeid Esmaeilzadeh Ph.D., and Alf LindbergM.D., Ph.D..
“We are very pleased and fortunate to add Maris Hartmanis, Karin Wingstrand and Peter Edmans’s deep experience and knowledge to the Xbrane Board of Directors,” said Saeid Esmaeilzadeh, chairman of Xbrane. Together with Alf they will play an important role in helping our management team to establish Xbrane as a Pioneer within the field of High Demand Complex Generics, developing and introducing therapies aimed towards a global market.
Maris Hartmanis, Ph.D., is an accomplished industrial executive and leader with almost 30 years of CEO, senior R&D management and Board experience from the international Life Science area. His experience stems from large organizations as well as entrepreneurial start-ups. Most recently he was the CEO of two Swedish public pharmaceutical companies, Medivir and BioPhausia. Maris has a Ph.D. degree in Biochemistry from the Royal Institute of Technology in Stockholm, where he is also an Associate Professor.
Karin Wingstrand M.Sc. has a broad experience of the international pharmaceutical industry from senior positions within regulatory, pharmaceutical and analytical R&D, project leadership as well as clinical. She has expertise in areas such as drug development, commercialization, implementation of new business strategies and production processes. Most recently Karin held the position of Global Head and Vice President of Clinical Development at AstraZeneca, where she worked for more than 25 years in various management roles.
Peter Edman Ph.D., has extensive experience in drug development from the pharmaceutical industry and has held a number of senior research leadership positions within Orexo, Sobi, Biovitrum, AstraZeneca, Astra and Pharmacia. He has also held a position as Associate Professor at the Swedish Medical Product Agency. In addition, Peter has been Professor in Pharmaceutical Formulation and Adjunct Professor in Drug Delivery at the Faculty of Pharmacy, University of Uppsala.
Xbrane is a commercial phase Swedish Biopharmaceutical Company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing biogenerics for injectable slow release drugs and proprietary high-yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company’s portfolio of High Demand Complex Generics.
Xbranes’s headquarters is located in Stockholm and the company’s in-house research and development facilities are in Sweden and Italy.
For further information, please contact:
Martin Åmark, CEO, Xbrane
M: +46 (0) 763-093 777
Siavash Bashiri, COO, Xbrane
M: +46 (0) 734-343 619